About Nautilus Biotechnology
Nautilus Biotechnology is a company based in Seattle (United States) founded in 2016 by Sujal Patel and Parag Mallick. Nautilus Biotechnology has raised $103.26 million across 5 funding rounds from investors including Amazon, Perceptive Advisors and Vulcan Aerospace. The company has 155 employees as of December 31, 2024. Nautilus Biotechnology offers products and services including Proteome Analysis Platform and Targeted Proteoform Analysis. Nautilus Biotechnology operates in a competitive market with competitors including Somalogic, Amunix, Biognosys, Elektrofi and ProteinSimple, among others.
- Headquarter Seattle, United States
- Employees 155 as on 31 Dec, 2024
- Founders Sujal Patel, Parag Mallick
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Nautilus Biotechnology, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$70.78 M (USD)-11.16as on Dec 31, 2024
-
EBITDA
-$75.12 M (USD)-6.64as on Dec 31, 2024
-
Total Equity Funding
$103.26 M (USD)
in 5 rounds
-
Latest Funding Round
$14.7 M (USD), Post-IPO
Aug 05, 2021
-
Investors
Amazon
& 7 more
-
Employee Count
155
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Nautilus Biotechnology
Nautilus Biotechnology is a publicly listed company on the NASDAQ with ticker symbol NAUT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Nautilus Biotechnology
Nautilus Biotechnology offers a comprehensive portfolio of products and services, including Proteome Analysis Platform and Targeted Proteoform Analysis.
Platform quantifies proteins for discovery in biological research applications.
Analyzes protein variants to drive insights in drug and biomarker fields.
People of Nautilus Biotechnology
Unlock access to complete
Unlock access to complete
Funding Insights of Nautilus Biotechnology
Nautilus Biotechnology has successfully raised a total of $103.26M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $14.7 million completed in August 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Nautilus Biotechnology
Nautilus Biotechnology has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Amazon, Perceptive Advisors and Vulcan Aerospace.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment management and philanthropic ventures linked to Bezos Expeditions.
|
Locked | Locked | Locked | |
|
Health-tech companies are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Early-stage venture capital investments are made in US geographies.
|
Locked | Locked | Locked |
Investor details for Nautilus Biotechnology
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Nautilus Biotechnology
Investment portfolio details for Nautilus Biotechnology
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Nautilus Biotechnology
Detailed financials for Nautilus Biotechnology
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nautilus Biotechnology Comparisons
Peer comparison for Nautilus Biotechnology
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Nautilus Biotechnology
Nautilus Biotechnology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Somalogic, Amunix, Biognosys, Elektrofi and ProteinSimple, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Protein-based assays are developed for life science research.
|
|
| Locked | Locked | Locked |
Peptide-based therapeutics are developed for cancers and immune disorders.
|
|
| Locked | Locked | Locked |
Proteomics services are delivered via discovery and targeted platforms.
|
|
| Locked | Locked | Locked |
Digital platform transforming the delivery of biologic medicines
|
|
| Locked | Locked | Locked |
Provider tools to help researchers with protein analysis
|
Detailed competitors of Nautilus Biotechnology
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nautilus Biotechnology
Complete news archive for Nautilus Biotechnology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nautilus Biotechnology
Nautilus Biotechnology was founded in 2016 and raised its 1st funding round 2 years after it was founded.
Nautilus Biotechnology is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Sujal Patel is the current CEO of Nautilus Biotechnology. They have also founded this company.
Nautilus Biotechnology is a funded company, having raised a total of $103.26M across 5 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Nautilus Biotechnology is 155.
Nautilus Biotechnology was founded in 2016 and is headquartered in Seattle, United States. A proteomics platform is being developed to analyze and quantify proteins in the human proteome, utilizing patent-protected technology. This platform supports applications in drug development and precision medicine within the biotechnology sector. Operations focus on enhancing protein quantification sensitivity for research purposes.
Nautilus Biotechnology offers Proteome Analysis Platform and Targeted Proteoform Analysis.
Yes, Nautilus Biotechnology is publicly traded on NASDAQ under the ticker symbol NAUT.
Nautilus Biotechnology has 8 investors. Key investors include Amazon, Perceptive Advisors, Vulcan Aerospace, Bezos Expeditions, and defy vc.
The ticker symbol of Nautilus Biotechnology is NAUT on NASDAQ.